Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4557486 | 0.91 | — | — | |
| Phosphoric Acid SCHEMBL9574523 | 0.85 | FDPS (0.43) | — | |
| SCHEMBL437885 | 0.72 | SMPD1 (0.33) | — | |
| SCHEMBL27776897 | 0.72 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL17662046 | 0.70 | — | — | |
| SCHEMBL14961843 | 0.70 | — | — | |
| SCHEMBL6831466 | 0.69 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL10608081 | 0.69 | — | — | |
| SCHEMBL5617495 | 0.68 | ALDH1A1 (0.35) | ALDH1A1 | |
| Phosphoric Acid SCHEMBL15252855 | 0.68 | LMNA (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2117527-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF SENILE DEMENTIA OF THE ALZHEIMER'S TYPE | MED LIFE DISCOVERIES LP (CA) | 2020-06-17 | — | — | EP | disclosed |
| EP-2620147-B1 | Compounds for lowering cholesterol | MED LIFE DISCOVERIES LP (CA) | 2020-06-03 | — | — | EP | disclosed |
| US-10123989-B2 | Method of lowering cholesterol | MED-LIFE DISCOVERIES LP (CA) | 2018-11-13 | — | — | US | disclosed |
| US-20170056363-A1 | Method of lowering cholesterol | MED-LIFE DISCOVERIES LP (CA) | 2017-03-02 | — | — | US | disclosed |
| US-9517222-B2 | Method for the treatment of senile dementia of the Alzheimer's type | PHENOMENOME DISCOVERIES INC. (CA) | 2016-12-13 | — | — | US | disclosed |
| US-20160015673-A1 | METHOD FOR LOWERING CHOLESTEROL | MED-LIFE DISCOVERIES LP (CA) | 2016-01-21 | — | — | US | disclosed |
| US-20150306057-A1 | METHOD FOR THE TREATMENT OF SENILE DEMENTIA OF THE ALZHEIMER'S TYPE | MED-LIFE DISCOVERIES LP (CA) | 2015-10-29 | — | — | US | disclosed |
| US-9034923-B2 | Methods for the treatment of senile dementia of the alzheimer's type | PHENOMENOME DISCOVERIES INC. (CA) | 2015-05-19 | — | — | US | disclosed |
| US-8993623-B2 | Method for lowering cholesterol | PHENOMENOME DISCOVERIES INC. (CA) | 2015-03-31 | — | — | US | disclosed |
| WO-2014167074-A1 | METHODS FOR MODULATING RNA ALTERNATIVE SPLICING IN A SUBJECT IN NEED THEREOF | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2014-10-16 | — | — | WO | disclosed |
| WO-2008095275-A1 | METHODS FOR THE TREATMENT OF SENILE DEMENTIA OF THE ALZHEIMER'S TYPE | PHENOMENOME DISCOVERIES INC. (CA) | 2008-08-14 | — | — | WO | disclosed |
| EP-1906725-A2 | ENHANCEMENT OF HYDROXY FATTY ACID ACCUMULATION IN OILSEED PLANTS | Washington State University (US) | 2008-04-09 | — | — | EP | disclosed |
| US-7175679-B2 | Oligopeptide treatment of NF-κB mediated inflammation | BIOTEMPT B.V. (NL) | 2007-02-13 | — | — | US | disclosed |
| WO-2006127655-A2 | ENHANCEMENT OF HYDROXY FATTY ACID ACCUMULATION IN OILSEED PLANTS | WASHINGTON STATE UNIVERSITY (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20060141493-A1 | Atherosclerotic phenotype determinative genes and methods for using the same | DUKE UNIVERSITY OFFICE OF SCIENCE AND TECHNOLOGY (US) | 2006-06-29 | — | — | US | disclosed |
| WO-2006026074-A2 | ATHEROSCLEROTIC PHENOTYPE DETERMINATIVE GENES AND METHODS FOR USING THE SAME | DUKE UNIVERSITY (US) | 2006-03-09 | — | — | WO | disclosed |
| EP-1579383-A2 | BINARY PREDICTION TREE MODELING WITH MANY PREDICTORS AND ITS USES IN CLINICAL AND GENOMIC APPLICATIONS | Duke University (US) | 2005-09-28 | — | — | EP | disclosed |
| US-6936417-B2 | Gene expression in bladder tumors | AROS APPLIED BIOTECHNOLOGY APS (DK) | 2005-08-30 | — | — | US | disclosed |
| WO-2004038376-A2 | BINARY PREDICTION TREE MODELING WITH MANY PREDICTORS AND ITS USES IN CLINICAL AND GENOMIC APPLICATIONS | DUKE UNIVERSITY (US) | 2004-05-06 | — | — | WO | disclosed |
| US-6491922-B1 | ADMINISTERING LIPOPOLYSACCHARIDES AND/OR ANALOGUES AS ANTIINFLAMMATORY AGENTS TO MAMMALS | CORNELL RESEARCH FOUNDATION, INC. | 2002-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160015673-A1 | METHOD FOR LOWERING CHOLESTEROL | DLAT, SOAT2, CETP | ALDH1A1 807/4885 |
| US-20170056363-A1 | Method of lowering cholesterol | DLAT, SOAT2, CETP | ALDH1A1 1163/4885 |
| US-20150306057-A1 | METHOD FOR THE TREATMENT OF SENILE DEMENTIA OF THE ALZHEIMER'S TYPE | DLAT, HHAT, APP | ALDH1A1 686/4885 |
| US-10123989-B2 | Method of lowering cholesterol | CETP, HMGCR, LIPA | ALDH1A1 1080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.